

Mixed views on Myriad after Supreme Court agrees to rehear case

NEW YORK – Wall Street analysts took a mixed view of Myriad Genetics today following the announcement on Friday by the US Supreme Court that it would [review a lawsuit](#) challenging the company's patents related to the BRCA1 and BRCA2 genes.

View the original article here: [Analysts Provide Mixed Views on Myriad After Supreme Court Agrees to Rehear Patent Case](#)